Arca
Skip to content

Pre-eclampsia

Drug research and approvals for pre-eclampsia: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.

As of Nov 17, 2026, 140 studies of pre-eclampsia are recruiting on ClinicalTrials.gov, and Health Canada has authorized 2 drug trials for it since 2013.

  • Recruiting worldwide: 140
  • Trials authorized in Canada: 2
  • FDA orphan approvals: 0
  • EU medicines: 0

Recruiting Now

Newest start dates first, of 140 recruiting on ClinicalTrials.gov ↗

Drug Pipeline

19 in phase 3, 17 in phase 2, 6 in phase 1 or earlier; from ChEMBL's drug indications, furthest stage reached for this condition
Aspirin
Phase 3 Cyclooxygenase inhibitor
Pravastatin
Phase 3 HMG-CoA reductase inhibitor
Labetalol
Phase 3 Adrenergic receptor antagonist
Esomeprazole
Phase 3 Potassium-transporting ATPase inhibitor
Metformin
Phase 3 Mitochondrial complex I (NADH dehydrogenase) inhibitor
Misoprostol
Phase 3 Prostanoid EP3 receptor agonist
Furosemide
Phase 3 Sodium-(potassium)-chloride cotransporter 2 inhibitor
Lidocaine
Phase 3 Sodium channel alpha subunit blocker
Ephedrine
Phase 3 Adrenergic receptor agonist
Hydrochlorothiazide
Phase 3 Thiazide-sensitive sodium-chloride cotransporter inhibitor
Hydroxychloroquine
Phase 3 Ferriprotoporphyrin IX inhibitor
Atorvastatin
Phase 3 HMG-CoA reductase inhibitor
Metaraminol
Phase 3 Adrenergic receptor alpha-1 agonist
Nifedipine
Phase 3 Voltage-gated L-type calcium channel blocker
Nicardipine
Phase 3 Voltage-gated L-type calcium channel blocker
Antithrombin alfa
Phase 3 Coagulation factor X inhibitor
Ubidecarenone
Phase 3 Supplement
Urapidil
Phase 3
Sildenafil
Phase 2 Phosphodiesterase 5A inhibitor
Dexmedetomidine
Phase 2 Adrenergic receptor alpha-2 agonist
Ascorbic acid
Phase 2 Supplement
Acetaminophen
Phase 2 Cyclooxygenase inhibitor
Celecoxib
Phase 2 Cyclooxygenase-2 inhibitor
Enalapril
Phase 2 Angiotensin-converting enzyme inhibitor
Ibuprofen
Phase 2 Cyclooxygenase inhibitor
Ketorolac
Phase 2 Cyclooxygenase inhibitor
Oxycodone
Phase 2 Mu opioid receptor agonist
Progesterone
Phase 2 Progesterone receptor agonist

Showing the 30 furthest along of 42 in trials.

How Its Trials Ended

765 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrong

Of the 102 whose ending is known, 25% met their primary endpoint, 19% missed it and 56% stopped early.

  • Completed, result not reported32042%
  • Ongoing18224%
  • Status unknown16121%
  • Stopped: other or unclear324%
  • Met its primary endpoint263%
  • Missed its primary endpoint192%
  • Stopped: enrollment or feasibility182%
  • Stopped: lack of efficacy30%
  • Stopped: sponsor or business decision30%
  • Stopped: safety10%

Trials Authorized in Canada

Newest first; search them all in Canada trials
Mar 3, 2026A phase 2, open-label dose-escalation and expansion study of dm199 in early-onset preeclampsia under expectant managementDM199 (rinvecalinase alfa)Diamedica IncPending
Dec 5, 2013Essai randomisé comparant l’effet de l’aspirine à faible dose au placebo sur le poids de naissance des grossesses gémellaires (étude gap)Acetylsalicylic acidCentre Hospitalier Affilié Universitaire De QuéBecPending

Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA

Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.